Utilizing AI and Social Media Analytics to Discover Adverse Side Effects of GLP-1 Receptor Agonists

• URL: http://arxiv.org/abs/2404.01358v1
• Date: Mon, 1 Apr 2024 09:48:14 GMT
• Title: Utilizing AI and Social Media Analytics to Discover Adverse Side Effects of GLP-1 Receptor Agonists
• Authors: Alon Bartal, Kathleen M. Jagodnik, Nava Pliskin, Abraham Seidmann,
• Abstract summary: Adverse side effects (ASEs) of drugs, revealed after FDA approval, pose a threat to patient safety. We developed a digital methodology capable of analyzing massive public data from social media. We uncovered 21 potentials associated with the glucagon-like peptide 1 receptor agonists (GLP-1 RA) market.
• Score: 0.0
• License: http://creativecommons.org/licenses/by-nc-sa/4.0/
• Abstract: Adverse side effects (ASEs) of drugs, revealed after FDA approval, pose a threat to patient safety. To promptly detect overlooked ASEs, we developed a digital health methodology capable of analyzing massive public data from social media, published clinical research, manufacturers' reports, and ChatGPT. We uncovered ASEs associated with the glucagon-like peptide 1 receptor agonists (GLP-1 RA), a market expected to grow exponentially to $133.5 billion USD by 2030. Using a Named Entity Recognition (NER) model, our method successfully detected 21 potential ASEs overlooked upon FDA approval, including irritability and numbness. Our data-analytic approach revolutionizes the detection of unreported ASEs associated with newly deployed drugs, leveraging cutting-edge AI-driven social media analytics. It can increase the safety of new drugs in the marketplace by unlocking the power of social media to support regulators and manufacturers in the rapid discovery of hidden ASE risks.

Related papers

• Proteomic Learning of Gamma-Aminobutyric Acid (GABA) Receptor-Mediated Anesthesia [6.428865757072811]
  We introduce a proteomic learning of GABA receptor-mediated anesthesia based on 24 GABA receptor subtypes. We curated a dataset comprising 136 targets from a pool of 980 targets within the PPI networks. We evaluated the side effects and repurposing potential of over 180,000 drug candidates targeting the GABRA5 receptor.
  arXiv  Detail & Related papers  (2025-01-06T07:55:39Z)
• Learning to Describe for Predicting Zero-shot Drug-Drug Interactions [54.172575323610175]
  Adverse drug-drug interactions can compromise the effectiveness of concurrent drug administration. Traditional computational methods for DDI prediction may fail to capture interactions for new drugs due to the lack of knowledge. We propose TextDDI with a language model-based DDI predictor and a reinforcement learning(RL)-based information selector.
  arXiv  Detail & Related papers  (2024-03-13T09:42:46Z)
• CDRH Seeks Public Comment: Digital Health Technologies for Detecting Prediabetes and Undiagnosed Type 2 Diabetes [0.0]
  FDA asked for public comments on role of digital health technologies (DHTs) in detecting prediabetes and undiagnosed type 2 diabetes. DHTs capture health signals like glucose, diet, symptoms and community insights. Subpopulations that could benefit most from remote screening tools include rural residents, minority groups, high-risk individuals and those with limited healthcare access.
  arXiv  Detail & Related papers  (2023-12-18T14:20:53Z)
• Knowledge-Driven New Drug Recommendation [88.35607943144261]
  We develop a drug-dependent multi-phenotype few-shot learner to bridge the gap between existing and new drugs. EDGE eliminates the false-negative supervision signal using an external drug-disease knowledge base. Results show that EDGE achieves 7.3% improvement on the ROC-AUC score over the best baseline.
  arXiv  Detail & Related papers  (2022-10-11T16:07:52Z)
• AI-based Approach for Safety Signals Detection from Social Networks: Application to the Levothyrox Scandal in 2017 on Doctissimo Forum [1.4502611532302039]
  We propose an AI-based approach for the detection of potential pharmaceutical safety signals from patients' reviews. We focus on the Levothyrox case in France which triggered huge attention from the media following the change of the medication formula. We investigate various NLP-based indicators extracted from patients' reviews including words and n-grams frequency, semantic similarity, Adverse Drug Reactions mentions, and sentiment analysis.
  arXiv  Detail & Related papers  (2022-02-01T10:17:32Z)
• Improved Drug-target Interaction Prediction with Intermolecular Graph Transformer [98.8319016075089]
  We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture. Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively. IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
  arXiv  Detail & Related papers  (2021-10-14T13:28:02Z)
• AI and the future of pharmaceutical research [0.0]
  The paper argues that continued innovation in pharmaceutical AI will enable rapid development of safe and effective therapies for previously untreatable diseases. The industry already reported results such as a 10-fold reduction in drug molecule discovery times. The paper concludes that the focus on pharmaceutical AI put the industry on a trajectory towards another significant disruption: open data sharing and collaboration.
  arXiv  Detail & Related papers  (2021-06-25T17:56:36Z)
• SafeDrug: Dual Molecular Graph Encoders for Safe Drug Recommendations [59.590084937600764]
  We propose a DDI-controllable drug recommendation model named SafeDrug to leverage drugs' molecule structures and model DDIs explicitly. On a benchmark dataset, our SafeDrug is relatively shown to reduce DDI by 19.43% and improves 2.88% on Jaccard similarity between recommended and actually prescribed drug combinations over previous approaches.
  arXiv  Detail & Related papers  (2021-05-05T00:20:48Z)
• Preliminary Results from a Peer-Led, Social Network Intervention, Augmented by Artificial Intelligence to Prevent HIV among Youth Experiencing Homelessness [47.21347530335741]
  Each year, there are nearly 4 million youth experiencing homelessness in the United States with HIV prevalence ranging from 3 to 11.5%. PCA models for HIV prevention have been used successfully in many populations, but there have been notable failures. We tested a new PCA intervention for YEH, with three arms: (1) an arm using an artificial intelligence (AI) planning algorithm to select PCA, (2) a popularity arm--operationalized as highest degree centrality (DC), and (3) an observation only comparison group (OBS) Both the AI and DC arms showed improvements over time. AI-based PCA selection led to better
  arXiv  Detail & Related papers  (2020-07-11T02:17:53Z)
• Detecting Adverse Drug Reactions from Twitter through Domain-Specific Preprocessing and BERT Ensembling [0.0]
  We aim to develop a deep learning model to classify ADRs within Twitter tweets that contain drug mentions. Our approach involved fine-tuning $BERT_LARGE$ and two domain-specific BERT implementations, $BioBERT$ and $Bio + clinicalBERT$. Our final model resulted in state-of-the-art performance on both $F_1$-score (0.6681) and recall (0.7700) outperforming all models submitted in SMM4H 2019 and during post-evaluation to date.
  arXiv  Detail & Related papers  (2020-05-11T20:49:24Z)
• Digital Ariadne: Citizen Empowerment for Epidemic Control [55.41644538483948]
  The COVID-19 crisis represents the most dangerous threat to public health since the H1N1 pandemic of 1918. Technology-assisted location and contact tracing, if broadly adopted, may help limit the spread of infectious diseases. We present a tool, called 'diAry' or 'digital Ariadne', based on voluntary location and Bluetooth tracking on personal devices.
  arXiv  Detail & Related papers  (2020-04-16T15:53:42Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.